FDA gives tentative nod to Zydus Cadila for generic Tradjenta  

Adult patients with Type 2 diabetes will soon have a new generic treatment.

The Food and Drug Administration has given tentative approval for Zydus Cadila’s linagliptin tablets in a dosage strength of 5 mg.

The medication is the generic of Boehringer Ingelheim’s Tradjenta.

Linagliptin tablets are used as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

The medication will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.